Rheumatoid Arthritis (RA) is a chronic disease that displays a significant variation in clinical picture, response to therapy, and longer-term outcomes. With few and crude predictors available, our means for an individualised strategy are limited. A personalised medicine (PM) approach to RA requires new biomarkers, and algorithms, to support diagnosis and choice of effective treatment. For PM to transform clinical rheumatology practice, new tools to bring such algorithms to patients and to clinical practice are needed. ScandRA builds on our successful collaboration between academia, healthcare, patients, and the private sector in biomarker technologies, data interoperability and e-health. In the Scandinavian countries, we have collected large amounts of information on patients with RA in our longitudinal prospective registers and biobanks, the largest and most detailed world-wide. We are now uniquely positioned i) to make detailed clinical data on RA disease activity, treatment, and life-style available for joint analyses with novel genomic- and biomarker-data from blood samples from these cohorts, ii) to take the next step, towards integration of the emergent results into clinical practice. Planned work include i) knowledge generation from novel analyses of our RA data, ii) value creation through development of decision support tools based on these insights, and iii) work with the ethical, legal and social challenges that are necessary for successful implementation.